Sorry, you need to enable JavaScript to visit this website.

There is a growing demand for biosimilar therapies that treat chronic diseases, including cancer, diabetes, and rheumatoid arthritis. But patients frequently don’t have access to these alternative treatments that are often lower cost.

Congress is considering a bill that could make biosimilars more accessible to patients who depend on them.

The bill would eliminate patient out-of-pocket costs under Medicare Part B for biosimilars — FDA-approved and often lower-cost alternatives to biologic therapies. The reduced costs would make it easier for patients to access to these equally safe and effective therapies and potentially save the American healthcare system up to $54 billion over the next 10 years.

Tell your congressional representative to reduce patient out-of-pocket costs by supporting the $0 Biosimilars Copay bill.

Act now! Send the letter below to your representative today.

This effort is supported by Pfizer – Ready for Cures. Click here for more information on biosimilars.